- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.03. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 26.03.2024 | 125 | Xetra Newsboard | The following instruments on XETRA do have their first trading 26.03.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 26.03.2024
Aktien
1 US07782B1044 BELITE BIO Inc. ADR
Anleihen/ETF
1... ► Artikel lesen | |
| 22.03. | Belite Retreats on Start of Clinical Trial | 2 | Baystreet.ca | ||
| 22.03. | Belite Bio completes enrollment for STGD1 treatment trial | 1 | Investing.com | ||
| 22.03. | Belite Bio, Inc: Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan | 355 | GlobeNewswire (Europe) | Tinlarebant is Belite Bio's orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related... ► Artikel lesen | |
| 22.03. | BELITE BIO, INC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 12.03. | Belite Bio GAAP EPS of -$0.25 beats by $0.05 | 2 | Seeking Alpha | ||
| 12.03. | Belite Bio, Inc: Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website | 1 | GlobeNewswire (USA) | ||
| 12.03. | BELITE BIO, INC - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 12.03. | Belite Bio, Inc: Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | 66 | GlobeNewswire (Europe) | Tinlarebant is Belite Bio's orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related... ► Artikel lesen | |
| 12.03. | BELITE BIO, INC - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 06.03. | Belite Bio, Inc: Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results | 1 | GlobeNewswire (USA) | ||
| 07.02. | Belite Bio, Inc: Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference | - | GlobeNewswire (USA) | ||
| 14.12.23 | Expert Ratings for Belite Bio | 1 | Benzinga.com | ||
| 30.11.23 | Belite Bio, Inc: Belite Bio to Participate in the Benchmark Company's Upcoming Discovery One-on-One Investor Conference | 1 | GlobeNewswire (USA) | ||
| 14.11.23 | Belite Bio GAAP EPS of -$0.40 misses by $0.08 | - | Seeking Alpha | ||
| 14.11.23 | Belite Bio, Inc: Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results | 194 | GlobeNewswire (Europe) | Completed enrollment in pivotal Phase 3 "DRAGON" trial for Tinlarebant in adolescent Stargardt disease ("STGD1") with 104 subjects enrolled across 11 countries worldwideFirst subject dosed with Tinlarebant... ► Artikel lesen | |
| 06.11.23 | BELITE BIO, INC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.10.23 | Belite Bio, Inc: Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 09.08.23 | Belite Bio, Inc: Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results | 217 | GlobeNewswire (Europe) | Completed enrollment in pivotal Phase 3 "DRAGON" trial for Tinlarebant in adolescent Stargardt disease ("STGD1") with 100 subjects enrolled across 11 countries worldwideFirst subject dosed with Tinlarebant... ► Artikel lesen | |
| 24.07.23 | Belite Bio, Inc: Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease | 336 | GlobeNewswire (Europe) | Tinlarebant (a/k/a LBS-008) is Belite Bio's orally administered tablet intended to slow disease progression in patients with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related... ► Artikel lesen |
Seite:
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 13,260 | -1,41 % | EQS-AFR: Evotec SE: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Evotec SE
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Evotec SE: Vorabbekanntmachung über die Veröffentlichung... ► Artikel lesen | |
| BIOFRONTERA | 0,312 | -4,29 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Kapitalerhöhung aus Genehmigtem Kapital | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Kapitalerhöhung aus Genehmigtem Kapital
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
Leverkusen (pta/04.04.2024/19:45)... ► Artikel lesen | |
| BRAIN BIOTECH | 2,970 | +3,12 % | EQS-News: BRAIN Biotech AG unternimmt nächsten Schritt zur Optimierung der Gruppenstruktur | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Sonstiges
BRAIN Biotech AG unternimmt nächsten Schritt zur Optimierung der Gruppenstruktur
16.04.2024 / 11:20 CET/CEST
Für... ► Artikel lesen | |
| OCUGEN | 1,227 | -0,65 % | Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410-A Modifier Gene Therapy | ||
| MAINZ BIOMED | 0,850 | +0,24 % | MAINZ BIOMED N.V. - 6-K, Report of foreign issuer | ||
| VIKING THERAPEUTICS | 59,28 | -0,40 % | Viking Therapeutics (VKTX) to Report Q1 Earnings: What's in the Cards? | ||
| BURCON NUTRASCIENCE | 0,145 | +3,57 % | Burcon NutraScience Corporation: HPS and Burcon to Showcase High Purity 95% Hempseed Protein Isolate at SupplySide East | Vancouver, British Columbia--(Newsfile Corp. - April 10, 2024) - Burcon NutraScience Corporation (TSX: BU) ("Burcon" or the "Company"), a global technology leader in the development of plant-based... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 2,591 | -0,35 % | BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia | Company plans to initiate trial following recent meeting with FDA No FDA-approved therapies for acute treatment of AAD are currently available NEW HAVEN, Conn., April 10, 2024 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| ARGENX | 339,50 | +0,38 % | The Analyst Verdict: argenx In The Eyes Of 12 Experts | ||
| VAXXINITY | 0,478 | +2,93 % | Vaxxinity, Inc.: Vaxxinity Issues Shareholder Letter | ||
| BEAM THERAPEUTICS | 23,900 | -1,69 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| QIAGEN | 37,470 | +1,19 % | Kursverluste für das Wertpapier von Qiagen NV (37,815 €) | An der Börse liegt der Anteilsschein von Qiagen NV gegenwärtig im Minus. Das Papier notiert derzeit bei 37,82 Euro. Ein Verlust von 0,79 Prozent steht gegenwärtig für das Wertpapier von Qiagen NV zu... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 9,100 | -3,70 % | Arcutis Biotherapeutics, Inc.: Arcutis Appoints David Topper as Chief Financial Officer | WESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,350 | -0,68 % | Recursion Pharmaceuticals, Inc.: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer | Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of DirectorsSALT LAKE... ► Artikel lesen | |
| ADMA BIOLOGICS | 6,270 | +1,13 % | ADMA Biologics, Inc.: ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV & BIVIGAM | FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf Life Extends the Prior Room Temperature Storage Allowance for... ► Artikel lesen |
Das Unternehmen BELITE BIO INC ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,20 % bei einem Aktienkurs von 31,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
